{"url_path":"/sec/allo/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1737287/0001628280-26-034585-index.html","accession_number":"0001628280-26-034585","cik":"0001737287","ticker":"ALLO","issuer_name":"Allogene Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737287/0001628280-26-034585-index.html","primary_entity_key":"0001737287","primary_entity_name":"Allogene Therapeutics, Inc."},"word_count":560,"has_tables":true,"body_markdown":"allo-20260331\n12-31false00017372872026Q1http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrenthttp://allogene.com/20260331#AccruedAndOtherLiabilitiesCurrenthttp://allogene.com/20260331#AccruedAndOtherLiabilitiesCurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureallo:patientiso4217:EURutr:sqftallo:renewalallo:companyallo:propertyallo:segment00017372872026-01-012026-03-3100017372872026-05-1100017372872026-03-3100017372872025-12-3100017372872025-01-012025-03-310001737287us-gaap:CommonStockMember2025-12-310001737287us-gaap:AdditionalPaidInCapitalMember2025-12-310001737287us-gaap:RetainedEarningsMember2025-12-310001737287us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001737287us-gaap:CommonStockMember2026-01-012026-03-310001737287us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001737287allo:ATMOfferingMember2026-01-012026-03-310001737287allo:ATMOfferingMemberus-gaap:CommonStockMember2026-01-012026-03-310001737287allo:ATMOfferingMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001737287us-gaap:RetainedEarningsMember2026-01-012026-03-310001737287us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001737287us-gaap:CommonStockMember2026-03-310001737287us-gaap:AdditionalPaidInCapitalMember2026-03-310001737287us-gaap:RetainedEarningsMember2026-03-310001737287us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001737287us-gaap:CommonStockMember2024-12-310001737287us-gaap:AdditionalPaidInCapitalMember2024-12-310001737287us-gaap:RetainedEarningsMember2024-12-310001737287us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-3100017372872024-12-310001737287us-gaap:CommonStockMember2025-01-012025-03-310001737287us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001737287allo:ATMOfferingMember2025-01-012025-03-310001737287allo:ATMOfferingMemberus-gaap:CommonStockMember2025-01-012025-03-310001737287allo:ATMOfferingMemberus-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001737287us-gaap:RetainedEarningsMember2025-01-012025-03-310001737287us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001737287us-gaap:CommonStockMember2025-03-310001737287us-gaap:AdditionalPaidInCapitalMember2025-03-310001737287us-gaap:RetainedEarningsMember2025-03-310001737287us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3100017372872025-03-3100017372872019-11-300001737287allo:AtTheMarketOfferingMember2026-01-012026-03-310001737287us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001737287us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2026-03-310001737287us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001737287us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001737287us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001737287us-gaap:MoneyMarketFundsMember2026-03-310001737287us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2026-03-310001737287us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2026-03-310001737287us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2026-03-310001737287us-gaap:CommercialPaperMember2026-03-310001737287us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001737287us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001737287us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001737287us-gaap:CorporateBondSecuritiesMember2026-03-310001737287us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001737287us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001737287us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001737287us-gaap:USTreasurySecuritiesMember2026-03-310001737287us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001737287us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001737287us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel3Member2026-03-310001737287us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2026-03-310001737287us-gaap:FairValueInputsLevel1Member2026-03-310001737287us-gaap:FairValueInputsLevel2Member2026-03-310001737287us-gaap:FairValueInputsLevel3Member2026-03-310001737287us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001737287us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001737287us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2025-12-310001737287us-gaap:MoneyMarketFundsMember2025-12-310001737287us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2025-12-310001737287us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2025-12-310001737287us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2025-12-310001737287us-gaap:CommercialPaperMember2025-12-310001737287us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001737287us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001737287us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001737287us-gaap:CorporateBondSecuritiesMember2025-12-310001737287us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001737287us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001737287us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001737287us-gaap:USTreasurySecuritiesMember2025-12-310001737287us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001737287us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001737287us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel3Member2025-12-310001737287us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2025-12-310001737287us-gaap:FairValueInputsLevel1Member2025-12-310001737287us-gaap:FairValueInputsLevel2Member2025-12-310001737287us-gaap:FairValueInputsLevel3Member2025-12-310001737287us-gaap:LeaseholdImprovementsMember2026-03-310001737287us-gaap:LeaseholdImprovementsMember2025-12-310001737287allo:LaboratoryEquipmentMember2026-03-310001737287allo:LaboratoryEquipmentMember2025-12-310001737287allo:ComputerEquipmentAndPurchasedSoftwareMember2026-03-310001737287allo:ComputerEquipmentAndPurchasedSoftwareMember2025-12-310001737287us-gaap:FurnitureAndFixturesMember2026-03-310001737287us-gaap:FurnitureAndFixturesMember2025-12-310001737287allo:WorkforceReductionMember2025-05-122025-05-120001737287us-gaap:ResearchAndDevelopmentExpenseMemberallo:WorkforceReductionMember2025-01-012025-12-310001737287us-gaap:GeneralAndAdministrativeExpenseMemberallo:WorkforceReductionMember2025-01-012025-12-310001737287allo:ImpairmentLongLivedAssetHeldForUseMemberallo:WorkforceReductionMember2025-01-012025-12-310001737287allo:WorkforceReductionMember2026-01-012026-03-310001737287allo:WorkforceReductionMember2025-01-012025-03-310001737287allo:WorkforceReductionMember2026-03-310001737287allo:CaliforniaInstituteForRegenerativeMedicineCIRMMember2024-04-260001737287allo:CaliforniaInstituteForRegenerativeMedicineCIRMMember2024-04-262024-04-260001737287allo:CaliforniaInstituteForRegenerativeMedicineCIRMMember2025-04-280001737287allo:CaliforniaInstituteForRegenerativeMedicineCIRMMembersrt:MinimumMember2024-04-260001737287allo:CaliforniaInstituteForRegenerativeMedicineCIRMMembersrt:MaximumMember2024-04-260001737287allo:CaliforniaInstituteForRegenerativeMedicineCIRMMember2026-01-012026-03-310001737287allo:CaliforniaInstituteForRegenerativeMedicineCIRMMember2025-01-012025-03-310001737287allo:CaliforniaInstituteForRegenerativeMedicineCIRMMember2026-03-310001737287allo:AssetContributionAgreementMemberallo:PfizerIncMember2026-01-012026-03-310001737287allo:AssetContributionAgreementMemberallo:PfizerIncMember2025-01-012025-03-310001737287allo:ResearchCollaborationAndLicenseAgreementMemberallo:CellectisSAMemberallo:PreClinicalDevelopmentMilestoneMember2026-01-012026-03-310001737287allo:ResearchCollaborationAndLicenseAgreementMemberallo:CellectisSAMemberallo:PreClinicalDevelopmentMilestoneMember2025-01-012025-03-310001737287allo:PreClinicalDevelopmentMilestoneMemberallo:CellectisSAMember2026-01-012026-03-310001737287allo:PreClinicalDevelopmentMilestoneMemberallo:CellectisSAMember2025-01-012025-03-310001737287allo:LicenseAndCollaborationAgreementMemberallo:ServierMemberallo:RegulatoryMilestoneMember2024-05-100001737287allo:LicenseAndCollaborationAgreementMemberallo:ServierMemberallo:RegulatoryMilestoneMember2026-03-310001737287allo:LicenseAndCollaborationAgreementMemberallo:ServierMemberallo:SalesMilestoneMember2024-05-100001737287allo:LicenseAndCollaborationAgreementMemberallo:ServierMemberallo:RegulatoryMilestoneMember2026-02-132026-02-130001737287country:USallo:LicenseAndCollaborationAgreementMemberallo:ServierMember2024-05-100001737287allo:LicenseAndCollaborationAgreementMemberallo:ServierMemberallo:RegulatoryAndSalesMilestonesMember2026-01-012026-03-310001737287allo:LicenseAndCollaborationAgreementMemberallo:ServierMemberallo:RegulatoryAndSalesMilestonesMember2025-01-012025-03-310001737287allo:RegulatoryAndSalesMilestonesMember2026-01-012026-03-310001737287allo:RegulatoryAndSalesMilestonesMember2025-01-012025-03-310001737287allo:NotchTherapeuticsIncMember2025-12-310001737287allo:NotchTherapeuticsIncMember2026-03-310001737287allo:ResearchCollaborationAndLicenseAgreementMemberallo:NotchTherapeuticsIncMemberallo:PreClinicalDevelopmentMilestoneMember2025-01-012025-03-310001737287allo:ResearchCollaborationAndLicenseAgreementMemberallo:NotchTherapeuticsIncMemberallo:PreClinicalDevelopmentMilestoneMember2026-01-012026-03-310001737287allo:UniversityOfTexasMDAndersonCancerCenterMember2020-10-062020-10-060001737287allo:UniversityOfTexasMDAndersonCancerCenterMember2026-01-012026-03-310001737287allo:UniversityOfTexasMDAndersonCancerCenterMember2026-03-310001737287allo:UniversityOfTexasMDAndersonCancerCenterMember2025-03-310001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember2020-12-140001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMemberallo:OverlandPharmaceuticalsIncMember2020-12-140001737287allo:OverlandUSMemberallo:OverlandPharmaceuticalsIncMember2024-05-240001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMemberallo:OverlandPharmaceuticalsIncMember2024-05-240001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember2024-05-240001737287us-gaap:LicenseMemberallo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMembersrt:MaximumMember2024-05-240001737287allo:VotingInterestMemberallo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember2026-03-310001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember2025-12-310001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember2026-03-310001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember2026-01-012026-03-310001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMember2025-01-012025-03-310001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMemberus-gaap:LicenseMember2025-12-310001737287allo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMemberus-gaap:LicenseMember2026-03-310001737287allo:VotingInterestMemberallo:OverlandTherapeuticsFormerlyKnownAsAllogeneOverlandMemberus-gaap:SubsequentEventMember2026-05-120001737287allo:AntionCollaborationAgreementMember2023-07-012023-07-310001737287allo:AntionCollaborationAgreementMemberus-gaap:PreferredStockMember2023-07-012023-07-310001737287allo:AntionMember2023-07-310001737287allo:AntionCollaborationAgreementMemberus-gaap:OtherNoncurrentAssetsMember2026-03-310001737287allo:AntionCollaborationAgreementMemberus-gaap:OtherNoncurrentAssetsMember2025-12-310001737287allo:ForesightDiagnosticsCollaborationAgreementMember2024-01-032024-01-030001737287allo:ForesightDiagnosticsCollaborationAgreementMember2025-02-192025-02-190001737287allo:ForesightDiagnosticsCollaborationAgreementMember2026-01-012026-03-310001737287allo:ForesightDiagnosticsCollaborationAgreementMember2025-01-012025-03-310001737287allo:ForesightDiagnosticsCollaborationAgreementMemberallo:CurrentAccruedAndOtherLiabilitiesMember2026-03-310001737287allo:ForesightDiagnosticsCollaborationAgreementMemberallo:CurrentAccruedAndOtherLiabilitiesMember2025-12-310001737287allo:SouthSanFranciscoCaliforniaMember2018-08-310001737287allo:SouthSanFranciscoCaliforniaMember2021-12-310001737287allo:SouthSanFranciscoCaliforniaMember2018-10-310001737287allo:NewarkCaliforniaMember2019-02-012019-02-280001737287allo:NewarkCaliforniaMember2019-02-280001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2023-02-012023-02-280001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2026-02-012026-02-280001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2023-02-280001737287allo:HQLeaseMember2024-12-012025-01-310001737287allo:SouthSanFranciscoBuildingTwoMember2025-07-012025-07-3100017372872020-07-310001737287us-gaap:LetterOfCreditMember2025-12-310001737287us-gaap:LetterOfCreditMember2026-03-310001737287allo:TwoThousandEighteenPlanMember2025-12-310001737287allo:TwoThousandEighteenPlanMember2025-01-012025-12-310001737287allo:TwoThousandEighteenPlanMember2026-01-012026-03-310001737287allo:TwoThousandEighteenPlanMember2026-03-310001737287us-gaap:RestrictedStockUnitsRSUMember2025-12-310001737287us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-12-310001737287us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001737287us-gaap:RestrictedStockUnitsRSUMember2026-03-310001737287allo:CertainExecutiveOfficersAndOtherEmployeesMemberallo:PerformanceBasedRestrictedStockUnitsMember2026-03-310001737287allo:CertainExecutiveOfficersAndOtherEmployeesMemberallo:PerformanceBasedRestrictedStockUnitsMember2026-01-012026-03-310001737287allo:PerformanceBasedRestrictedStockUnitsMember2026-01-012026-03-310001737287allo:PerformanceBasedRestrictedStockUnitsMember2025-01-012025-03-310001737287allo:CertainExecutiveOfficersAndOtherEmployeesMemberallo:RestrictedStockUnitsRSUsWithMarketConditionMember2026-03-310001737287allo:CertainExecutiveOfficersAndOtherEmployeesMemberallo:RestrictedStockUnitsRSUsWithMarketConditionMember2026-01-012026-03-310001737287allo:CertainExecutiveOfficersAndOtherEmployeesMemberallo:RestrictedStockUnitsRSUsWithMarketConditionMember2025-01-012025-03-310001737287us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001737287us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001737287us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001737287us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001737287stpr:CAus-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2018-12-012018-12-310001737287stpr:CAus-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2018-12-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2022-07-012022-07-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2026-03-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2026-01-012026-03-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:SubleaseAgreementMember2025-01-012025-03-310001737287allo:PaymentsCommencingJanuary2021Memberus-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:ConsultingAgreementsMember2018-08-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:ConsultingAgreementsMember2026-01-312026-01-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:ConsultingAgreementsMember2026-01-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMembersrt:MaximumMemberallo:ConsultingAgreementsMember2018-08-012018-08-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:ConsultingAgreementsMember2026-01-012026-03-310001737287us-gaap:RelatedPartyMemberallo:BellcoCapitalLLCMemberallo:ConsultingAgreementsMember2025-01-012025-03-310001737287allo:April2026PublicOfferingMemberus-gaap:SubsequentEventMember2026-04-162026-04-160001737287allo:April2026PublicOfferingMemberus-gaap:SubsequentEventMember2026-04-160001737287us-gaap:RelatedPartyMemberallo:TPGCapitalBDLLCMemberallo:April2026PublicOfferingMemberus-gaap:SubsequentEventMemberallo:CoManagerAgreementMember2026-04-162026-04-160001737287us-gaap:RelatedPartyMemberallo:TPGCapitalBDLLCMemberallo:April2026PublicOfferingMemberus-gaap:SubsequentEventMemberallo:CoManagerAgreementMember2026-04-160001737287us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001737287us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001737287us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001737287us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001737287us-gaap:EmployeeStockMember2026-01-012026-03-310001737287us-gaap:EmployeeStockMember2025-01-012025-03-310001737287allo:ReportableSegmentMember2026-01-012026-03-310001737287allo:ReportableSegmentMember2025-01-012025-03-310001737287us-gaap:OverAllotmentOptionMemberus-gaap:SubsequentEventMember2026-04-162026-04-16\n\n[Table of Contents](#i458e61a10e714873b386bdbeb7020a31_7)\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, DC 20549\n\n________________________________________________________\n\nFORM 10-Q\n\n________________________________________________________\n\n(Mark One)\n\n☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from                      to                     \n\nCommission File Number: 001-38693\n\n________________________________________________________\n\nAllogene Therapeutics, Inc.\n\n(Exact Name of Registrant as Specified in its Charter)\n\n________________________________________________________\n\nDelaware82-3562771\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(I.R.S. Employer\n\nIdentification No.)\n\n210 East Grand Avenue, South San Francisco, California 94080\n\n(Address of principal executive offices including zip code)\n\nRegistrant’s telephone number, including area code: (650) 457-2700\n\nN/A\n\n(Former name, former address and former fiscal year, if changed since last report)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon Stock, $0.001 par value per shareALLOThe Nasdaq Stock Market LLC\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No  ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge Accelerated Filer☐Accelerated filer☐\n\nNon-accelerated filer☒Smaller reporting company☒\n\nEmerging growth company☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒\n\nAs of May 11, 2026, the registrant had 345,154,561 shares of common stock, $0.001 par value per share, outstanding.\n\n[Table of Contents](#i458e61a10e714873b386bdbeb7020a31_7)\n\nTable of Contents\n\nPage no.\n\n[PART I:](#i458e61a10e714873b386bdbeb7020a31_10) [FINANCIAL INFORMATION](#i458e61a10e714873b386bdbeb7020a31_10)\n\n[Item 1.](#i458e61a10e714873b386bdbeb7020a31_13)\n\n[Financial Statements - Unaudited](#i458e61a10e714873b386bdbeb7020a31_13)\n\n[1](#i458e61a10e714873b386bdbeb7020a31_13)\n\n[Condensed](#i458e61a10e714873b386bdbeb7020a31_16)[Balance Sheets](#i458e61a10e714873b386bdbeb7020a31_16)\n\n[1](#i458e61a10e714873b386bdbeb7020a31_16)\n\n[Condensed](#i458e61a10e714873b386bdbeb7020a31_19)[Statements of Operations and Comprehensive Loss](#i458e61a10e714873b386bdbeb7020a31_19)\n\n[2](#i458e61a10e714873b386bdbeb7020a31_19)\n\n[Condensed](#i458e61a10e714873b386bdbeb7020a31_22)[Statements of Stockholders’ Equity](#i458e61a10e714873b386bdbeb7020a31_22)\n\n[3](#i458e61a10e714873b386bdbeb7020a31_22)\n\n[Condensed](#i458e61a10e714873b386bdbeb7020a31_25)[Statements of Cash Flows](#i458e61a10e714873b386bdbeb7020a31_25)\n\n[4](#i458e61a10e714873b386bdbeb7020a31_25)\n\n[Notes to Condensed](#i458e61a10e714873b386bdbeb7020a31_28)[Financial Statements](#i458e61a10e714873b386bdbeb7020a31_28)\n\n[5](#i458e61a10e714873b386bdbeb7020a31_28)\n\n[Item 2.](#i458e61a10e714873b386bdbeb7020a31_70)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#i458e61a10e714873b386bdbeb7020a31_70)\n\n[19](#i458e61a10e714873b386bdbeb7020a31_70)\n\n[Item 3.](#i458e61a10e714873b386bdbeb7020a31_97)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#i458e61a10e714873b386bdbeb7020a31_97)\n\n[30](#i458e61a10e714873b386bdbeb7020a31_97)\n\n[Item 4.](#i458e61a10e714873b386bdbeb7020a31_100)\n\n[Controls and Procedures](#i458e61a10e714873b386bdbeb7020a31_100)\n\n[31](#i458e61a10e714873b386bdbeb7020a31_100)\n\n[PART II:](#i458e61a10e714873b386bdbeb7020a31_103) [OTHER INFORMATION](#i458e61a10e714873b386bdbeb7020a31_103)\n\n[Item 1.](#i458e61a10e714873b386bdbeb7020a31_106)\n\n[Legal Proceedings](#i458e61a10e714873b386bdbeb7020a31_106)\n\n[32](#i458e61a10e714873b386bdbeb7020a31_106)\n\n[Item 1A.](#i458e61a10e714873b386bdbeb7020a31_109)\n\n[Risk Factors](#i458e61a10e714873b386bdbeb7020a31_109)\n\n[32](#i458e61a10e714873b386bdbeb7020a31_109)\n\n[Item 2.](#i458e61a10e714873b386bdbeb7020a31_112)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#i458e61a10e714873b386bdbeb7020a31_112)\n\n[82](#i458e61a10e714873b386bdbeb7020a31_112)\n\n[Item 3.](#i458e61a10e714873b386bdbeb7020a31_115)\n\n[Defaults Upon Senior Securities](#i458e61a10e714873b386bdbeb7020a31_115)\n\n[82](#i458e61a10e714873b386bdbeb7020a31_115)\n\n[Item 4.](#i458e61a10e714873b386bdbeb7020a31_118)\n\n[Mine Safety Disclosures](#i458e61a10e714873b386bdbeb7020a31_118)\n\n[82](#i458e61a10e714873b386bdbeb7020a31_118)\n\n[Item 5.](#i458e61a10e714873b386bdbeb7020a31_121)\n\n[Other Information](#i458e61a10e714873b386bdbeb7020a31_121)\n\n[83](#i458e61a10e714873b386bdbeb7020a31_121)\n\n[Item 6.](#i458e61a10e714873b386bdbeb7020a31_124)\n\n[Exhibits](#i458e61a10e714873b386bdbeb7020a31_124)\n\n[83](#i458e61a10e714873b386bdbeb7020a31_124)\n\n[Signatures](#i458e61a10e714873b386bdbeb7020a31_127)\n\n[84](#i458e61a10e714873b386bdbeb7020a31_127)\n\ni\n\n[Table of Contents](#i458e61a10e714873b386bdbeb7020a31_7)\n\nPART I: FINANCIAL INFORMATION"}